Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis

Tracy Proverbs-Singh; Sophia K. Chiu; Ziyue Liu; Sonia Seng; Guru Sonpavde; Toni K. Choueiri; Che Kai Tsao; Menggang Yu; Noah M. Hahn; William K. Oh; Matthew D. Galsky

doi:10.1093/jnci/djs435

Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis

Tracy Proverbs-Singh, Sophia K. Chiu, Ziyue Liu, Sonia Seng, Guru Sonpavde, Toni K. Choueiri, Che Kai Tsao, Menggang Yu, Noah M. Hahn, William K. Oh, Matthew D. Galsky

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

Original language	English (US)
Pages (from-to)	1837-1840
Number of pages	4
Journal	Journal of the National Cancer Institute
Volume	104
Issue number	23
DOIs	https://doi.org/10.1093/jnci/djs435
State	Published - Dec 2012
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jnci/djs435

Cite this

@article{cab640bf89754580bdb268dc7340d366,

title = "Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis",

abstract = "Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.",

author = "Tracy Proverbs-Singh and Chiu, {Sophia K.} and Ziyue Liu and Sonia Seng and Guru Sonpavde and Choueiri, {Toni K.} and Tsao, {Che Kai} and Menggang Yu and Hahn, {Noah M.} and Oh, {William K.} and Galsky, {Matthew D.}",

note = "Funding Information: MDG is supported by a Prostate Cancer Foundation Young Investigator award.",

year = "2012",

month = dec,

doi = "10.1093/jnci/djs435",

language = "English (US)",

volume = "104",

pages = "1837--1840",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "23",

}

TY - JOUR

T1 - Arterial thromboembolism in cancer patients treated with cisplatin

T2 - A systematic review and meta-analysis

AU - Proverbs-Singh, Tracy

AU - Chiu, Sophia K.

AU - Liu, Ziyue

AU - Seng, Sonia

AU - Sonpavde, Guru

AU - Choueiri, Toni K.

AU - Tsao, Che Kai

AU - Yu, Menggang

AU - Hahn, Noah M.

AU - Oh, William K.

AU - Galsky, Matthew D.

N1 - Funding Information: MDG is supported by a Prostate Cancer Foundation Young Investigator award.

PY - 2012/12

Y1 - 2012/12

N2 - Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

AB - Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI 0.86 to 2.17; P .19). No increase in ATEs was detected in any prespecified subgroup.

UR - http://www.scopus.com/inward/record.url?scp=84870918725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870918725&partnerID=8YFLogxK

U2 - 10.1093/jnci/djs435

DO - 10.1093/jnci/djs435

M3 - Review article

C2 - 23093559

AN - SCOPUS:84870918725

SN - 0027-8874

VL - 104

SP - 1837

EP - 1840

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 23

ER -

Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this